 PALO ALTO, Calif., Feb. 02, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular anomalies, today announced that the first patient has been dosed in its Phase 12 clinical trial of BBP-681 also known as VT30 Topical Gel. 